Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Palisade Bio (PALI) over the last 16 years, with Q3 2025 value amounting to $7.5 million.

  • Palisade Bio's Shares Outstanding (Weighted Average) rose 39812.4% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 39812.4%. This contributed to the annual value of $1.4 million for FY2024, which is 21062.01% up from last year.
  • According to the latest figures from Q3 2025, Palisade Bio's Shares Outstanding (Weighted Average) is $7.5 million, which was up 39812.4% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, Palisade Bio's Shares Outstanding (Weighted Average) peaked at $12.1 million during Q3 2021, and registered a low of $287702.0 during Q1 2023.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $2.8 million, with a median of $1.1 million in 2022.
  • In the last 5 years, Palisade Bio's Shares Outstanding (Weighted Average) tumbled by 9540.4% in 2022 and then soared by 52432.17% in 2025.
  • Quarter analysis of 5 years shows Palisade Bio's Shares Outstanding (Weighted Average) stood at $12.1 million in 2021, then crashed by 92.72% to $880311.0 in 2022, then crashed by 48.2% to $456014.0 in 2023, then soared by 210.62% to $1.4 million in 2024, then surged by 427.64% to $7.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $7.5 million for Q3 2025, versus $4.8 million for Q2 2025 and $4.8 million for Q1 2025.